17,261 trials
Hyperoxaluria · Nephrolithiasis
Primary: Change From Baseline Period to Treatment Period 24-hour Urinary Oxalate Excretion — -13.92 mg/day
Diabetic Macular Edema
Primary: Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) From Baseline to 36 Weeks (Crossover Phase of the Study) — 5.3; 6.6…
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Overall Survival — 5.7 months — p=0.4
Low-grade B Cell Non-Hodgkin's Lymphoma · Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated
Primary: Complete Response Rate (CR + CRu) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC) — 67.8; 70.0; 68.1 percentage…
Cocaine Dependence
Primary: %Cocaine Free Urines — 52; 26 percent
Asthma
Primary: Mean Change From Baseline to End of Therapy in Asthma Control Questionnaire (ACQ) Score — -0.7; -0.3 units on a scale — p=0.0541
Pancreatic Cancer
Primary: Progression-Free Survival — 5.9; 6.1 weeks — p=0.1909
Colon Cancer · Rectal Cancer
Primary: Participants Exhibiting Immune Response — 11 Participants
Colorectal Neoplasms · Colorectal Carcinoma · Colorectal Tumors
Primary: Maximum Tolerated Dose (MTD) of ISIS 183750 in Advanced Solid Tumors — 1000 mg
Stress Disorders, Post-traumatic
Primary: Efficacy, Measured by Change in the Clinician-Administered PTSD Scale (CAPS) Score — -26.02; -27.33 score on a scale
HIV Infections
Primary: Percentage of Participants Experiencing Any Treatment-Emergent Study Dug-Related Adverse Event — 14.6 percentage of participants
Chronic Cluster Headache
Primary: A Change in the Frequency of Cluster Headache Attacks Per Week — -2.0; -7.6 CH attacks per week
Pathological Gambling
Primary: Subjective Reinforcement Self-report Scales — 4.8; 4.8; 9.5; 9.3 units on a scale
Diabetic Macular Edema
Primary: Overall Mean Change in Visual Acuity Scores at Month 6 Compared to Baseline — 58.8; 67.6; 8.8 letters
Adult T Cell Leukemia/Lymphoma
Primary: Response Rate (CR + Cru + PR)